This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously Presented) A compound of formula I

$$R^{1}O$$
 H
 OR^{4}
 R^{16}
 R^{15}
 R^{15}
 R^{16}
 R^{15}

in which radicals R¹, R², R³, R⁴ and R⁵ as well as R¹⁵ and R¹⁶ have the following meaning:

- R¹ is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR⁵, whereby R⁵ is a hydrogen atom, an alkyl or acyl radical with 1-10 carbon atoms in each case or an alkylaryl or aralkyl radical with 6-10 carbon atoms in each case,
- R² is a halogen atom or a CF₃ group,
- R^3 is a hydrogen atom or a group CH_2X , in which X stands for a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X stands for a radical $(CH_2)_nCH_2Y$ with n=0 or 1, and Y stands for a halogen atom,

whereby if

 R^2 is a halogen atom, R^3 in addition can mean a group $C_nF_mH_o$, whereby n=1, 2, 3, 4 or 5, m>1 and m+o=2n+1,

R⁴ means a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical with 6-10 carbon atoms or a radical –CONHR⁵, whereby R⁵ has the above-indicated meaning, and

R¹⁵ and R¹⁶ represent hydrogen atoms or together a double bond.

- Claim 2. (Previously Presented) A compound of formula 1 according to claim 1, in which R^2 is a chlorine or bromine atom.
- Claim 3. (Currently Amended) A compound of formula I according to claim 1, in which R^3 is a hydrogen atom or a group CH_2X ,

in which X <u>is</u> ean be-a hydrogen atom, a hydroxy group, a halogen atom, <u>or</u> a straight-chain or branched or unsaturated alkyl radical with 1-2 carbon atoms, a radical $(CH_2)_nCH_2Y$ with n = 0 or 1, and Y <u>ean be</u> is a halogen atom.

- Claim 4. (Previously Presented) A compound of formula I, according to claim 1, wherein R^4 is a hydrogen atom or an alkyl radical with 1 to 4 carbon atoms.
- Claim 5. (Previously Presented) A compound of formula I according to claim 1, in which R^1 means a hydrogen atom, R^2 stands for a hydrogen atom, a chlorine atom or a bromine atom, and R^3 can be a hydrogen atom, a methyl group, or a CH_2 -X group, whereby X stands for a fluorine, chlorine or bromine atom or a hydroxy group.
- **Claim 6.** (**Previously Presented**) A compound of formula I, according to claim 1, which is:
 - $4\hbox{-}[4'\hbox{-}Bromo\hbox{-}17\beta\hbox{-}hydroxy\hbox{-}3\hbox{-}oxoestra\hbox{-}4,9\hbox{-}dien\hbox{-}11\beta\hbox{-}yl]} benzaldehyde\hbox{-}1\hbox{-}(E)\hbox{-}oxime,$
- $\label{eq:def-def-def} 4-[4'-Bromo-17\beta-hydroxy-17\alpha-methyl-3-oxoestra-4,9-dien-11\beta-yl] benzaldehyde-1- \\ (E)-oxime,$
- 4-[4'-Bromo-17β-hydroxy-17α-trifluoromethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime,
 - $\hbox{$4$-[17\beta-Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11\beta-yl]$ benzaldehyde-1-(E)-oxime,}$

3

- 4-[17 β -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-O-acetyloxime,
- 4-[4'-Chloro-17β-hydroxy-17α-trifluoromethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime,

 $4-[4'-Chloro-17\beta-hydroxy-3-oxoestra-4,9-dien-11\beta-yl]$ benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17α-fluoromethyl-17β-hydroxy-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17α-chloromethyl-17β-hydroxy-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime,

 $\label{eq:def-def-def} 4-[4'-Bromo-17\alpha-bromomethyl-17\beta-hydroxy-3-oxoestra-4,9-dien-11\beta-yl] benzaldehyde-1-(E)-oxime,$

 $4\hbox{-}[4'\hbox{-}Chloro\hbox{-}17\beta\hbox{-}methoxy\hbox{-}3\hbox{-}oxoestra\hbox{-}4,9\hbox{-}dien\hbox{-}11\beta\hbox{-}yl]} benzaldehyde\hbox{-}1\hbox{-}(E)\hbox{-}oxime,$

 $\label{eq:def-def-def} 4-[4'-Chloro-17\alpha-chloromethyl-17\beta-hydroxy-3-oxoestra-4,9-dien-11\beta-yl] benzaldehyde-1-(E)-oxime,$

4-[17 β -Methoxy-4'-trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime, or

4-[4'-Chloro-17 β -hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime,

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of formula I according to claim 1 and a pharmaceutically compatible vehicle.

Claim 8. (Currently Amended) A method for female birth control, for treating dysfunctional bleeding, for treating dysmenorrhea, for inducing an amenorrhea, or for treating hormonal disorders in postmenopausal women, comprising administering to a female

$$R^{1}O$$
 H
 OR^{4}
 R^{16}
 R^{15}
 (I')

a compound of formula I'

in which radicals R¹, R², R³, R⁴ and R⁵ as well as R¹⁵ and R¹⁶ have the following meaning:

- R¹ is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR⁵, whereby R⁵ is a hydrogen atom, an alkyl or acyl radical with 1-10 carbon atoms in each case or an alkylaryl or aralkyl radical with 6-10 carbon atoms in each case,
- R² is a hydrogen atom, a halogen atom or a CF₃ group,
- R^3 is a hydrogen atom or a group CH_2X , in which X stands for a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X stands for a radical $(CH_2)_nCH_2Y$ with n=0 or 1, and Y stands for a halogen atom,

whereby if

 R^2 is a halogen atom, R^3 in addition can mean a group $C_nF_mH_o$, whereby n=1, 2, 3, 4 or 5, m>1 and m+o=2n+1,

means a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical with 6-10 carbon atoms or a radical –CONHR⁵, whereby R⁵ has the above-indicated meaning, and R¹⁵ and R¹⁶ represent hydrogen atoms or together a double bond.

Claim 9. (Previously Presented) A method for treating dysfunctional bleeding according to claim 8, comprising administering to a host in need thereof a compound of formula I'.

Claim 10. (Previously Presented) A method for treating dysmenorrhea according to claim 8, comprising administering to a host in need thereof a compound of formula I'.

- Claim 11. (Previously Presented) A method for inducing an amenorrhea according to claim 8, comprising administering to a host in need thereof a compound of formula I'.
- Claim 12. (Previously Presented) A method for treating hormonal disorders in postmenopausal women according to claim 8, comprising administering to a host in need thereof a compound of formula I'.
- Claim 13. (Previously Presented) A process for treating endometriosis or uterus myomatoses, comprising administering to a host in need thereof a compound of claim 1.
- **Claim 14.** (**Previously Presented**) A method according to claim 8, wherein the compound is administered in combination with at least one low-dose natural or synthetic estrogen.
- Claim 15. (Previously Presented) A method according to claim 14, comprising using an estrogen as its 3-sulfamate.
- Claim 16. (Previously Presented) A method according to claim 15, wherein the estrogen-3-sulfamate is 17β -hydroxy-estra-1,3,5(10)-trien-3yl-sulfamate.
- Claim 17. (Previously Presented) A method for the production of a pharmacological agent, comprising bringing together a compound of claim 1 and a pharmacologically acceptable carrier.
- **Claim 18.** (**Previously Presented**) A method for female birth control, comprising administering to a female a compound according to claim 1.
- **Claim 19**. **(Previously Presented)** A method according to claim 18, wherein the compound is administered in combination with at least one low-dose natural or synthetic

estrogen.

Claim 20. (Previously Presented) A method according to claim 19, comprising using an estrogen as its 3-sulfamate.

Claim 21. (Previously Presented) A method according to claim 13, wherein the compound is administered in combination with at least one low-dose natural or synthetic estrogen.

Claim 22. (Previously Presented) A method according to claim 21, comprising using an estrogen as its 3-sulfamate.